CSIMarket
 
Travere Therapeutics Inc   (TVTX)
Other Ticker:  
 
 
Price: $7.4900 $-0.04 -0.531%
Day's High: $7.805 Week Perf: -6.26 %
Day's Low: $ 7.46 30 Day Perf: -9.21 %
Volume (M): 2,332 52 Wk High: $ 23.18
Volume (M$): $ 17,466 52 Wk Avg: $12.54
Open: $7.68 52 Wk Low: $5.25



 Market Capitalization (Millions $) 556
 Shares Outstanding (Millions) 74
 Employees 500
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -111
 Cash Flow (TTM) (Millions $) -4
 Capital Exp. (TTM) (Millions $) 42

Travere Therapeutics Inc
Travere Therapeutics Inc. is a pharmaceutical company that specializes in developing and commercializing treatments for rare and complex diseases. The company was founded in 1988 as Raptor Pharmaceuticals Corp. and was later renamed TRC Capital Corporation in 2018 before changing to its current name in 2019.

Travere Therapeutics focuses on developing treatments for chronic kidney disease, a group of complex and progressive conditions that damage the kidneys over time, leading to a range of health problems. The company has several drugs in its pipeline aimed at treating various forms of chronic kidney disease and other rare disorders.

One of the company's key products is called JYNARQUEe (tolvaptan), a treatment for adult patients with autosomal dominant polycystic kidney disease (ADPKD). ADPKD is a genetic disorder that causes cysts to develop and enlarge in the kidneys, resulting in a range of complications including kidney failure, high blood pressure, and liver cysts. JYNARQUEe is the first FDA-approved treatment for ADPKD and works by decreasing the rate of kidney enlargement and disease progression.

Another product in Travere Therapeutics' pipeline is sparsentan, an investigational drug currently in Phase 3 clinical trials for the treatment of focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). FSGS and IgAN are two other types of chronic kidney disease that can lead to kidney failure if left untreated.

Travere Therapeutics also has a robust research and development program focused on the development of treatments for other rare and complex diseases. They have partnerships with other pharmaceutical companies and academic institutions to develop new therapies and bring them to market.

In addition to its drug development efforts, Travere Therapeutics is committed to working with patient advocacy groups to raise awareness about rare diseases and improve patient outcomes. The company also has a patient support program that provides assistance to patients who are prescribed its drugs, including financial assistance and access to educational resources.

Overall, Travere Therapeutics is a leading pharmaceutical company specializing in the development of treatments for rare and complex diseases, particularly chronic kidney disease. With an active pipeline of drug candidates and a commitment to patient advocacy, Travere Therapeutics is poised to make a significant impact on the healthcare industry.


   Company Address: 3611 Valley Centre Drive San Diego 92130 CA
   Company Phone Number: 969-7879   Stock Exchange / Ticker: NASDAQ TVTX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Travere Therapeutics Announces Inducement Grants to New Employees

Published Wed, Mar 13 2024 9:00 PM UTC

Travere Therapeutics, Inc. recently disclosed the issuance of inducement equity grants to four newly hired employees. This move aligns with the company's compensation strategy and complies with Nasdaq Listing Rule 5635(c)(4). The grants, comprising stock options and restricted stock units (RSUs), were awarded outside of Travere's 2018 Equity Incentive Plan, yet are bound by ...

Management Announcement

Travere Therapeutics Submits sNDA to FDA for FILSPARI in IgA Nephropathy, While Stock Rallies on Market Confidence

Published Mon, Mar 11 2024 11:05 AM UTC

Travere Therapeutics Aims for Full FDA Approval of FILSPARI in IgA Nephropathy as Stock Soars
Travere Therapeutics, a biopharmaceutical company dedicated to developing innovative therapies for rare diseases, has recently submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking full approval for their drug FILSPARI (spars...

Clinical Study

Sparsentan Gains Positive CHMP Opinion for Treating IgA Nephropathy in Europe: A Game-Changer for Travere Therapeutics and CSL Vifor

Published Fri, Feb 23 2024 12:05 PM UTC

In a significant breakthrough for the treatment of IgA nephropathy (IgAN), Travere Therapeutics and CSL Vifor have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding the conditional marketing authorization (CMA) of sparsentan in Europe. This promising development has the potential to revolutionize the management of IgAN, a ch...

Travere Therapeutics Inc

2 Is Travere Therapeutics Inc Facing a Financial Crisis Amidst the Fourth Quarter Earnings Report of 2023?

The recent financial report from Travere Therapeutics Inc paints a grim picture of the company's performance in the fourth quarter of 2023. With a shortfall per share of $-1.07, a significant increase from the previous year's $-0.98 per share, investors are rightfully concerned about the company's financial health. The fact that the company realized a net loss of $90.173 million, compared to $65.823 million a year ago, is further evidence of Travere Therapeutics Inc's struggles.
One of the most concerning aspects of the report is the decline in revenue, which tumbled by 31.5% to $145.24 million for the financial year 2023. This significant drop in revenue is a clear indication that Travere Therapeutics Inc is facing challenges in generating sustainable income. Additionally, the decrease in earnings per share to $-1.50 from $-4.37 in the previous fiscal year is a worrisome trend that investors should take note of.

Licensing Agreement

Travere Therapeutics' Licensing Agreement Brings Sparsentan to East Asia and Southeast Asia Regions

Published Thu, Jan 25 2024 9:05 PM UTC

Travere Therapeutics, a leading biopharmaceutical company, has recently entered into an exclusive licensing agreement with Renalys Pharma. This collaboration aims to develop and commercialize sparsentan, a breakthrough therapy for kidney patients, in the countries of Japan, South Korea, Taiwan, and Southeast Asian nations. The partnership comes as great news, offering hope a...






 

Travere Therapeutics Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Travere Therapeutics Inc does not provide revenue guidance.

Earnings Outlook
Travere Therapeutics Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com